{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:27:01Z","timestamp":1774056421915,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.vaccine.2020.03.054","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T01:02:50Z","timestamp":1586566970000},"page":"3968-3979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety of live attenuated herpes zoster vaccine in adults 70\u201379\u00a0years: A self-controlled case series analysis using primary care data from Australia\u2019s MedicineInsight program"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9459-2566","authenticated-orcid":false,"given":"James","family":"Totterdell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Glover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendal","family":"Chidwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4670-0638","authenticated-orcid":false,"given":"Tom","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4675-0232","authenticated-orcid":false,"given":"Kristine","family":"Macartney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2020.03.054_b0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S0950268801005921","article-title":"Epidemiology of varicella zoster virus infection in Canada and the United Kingdom","volume":"127","author":"Brisson","year":"2001","journal-title":"Epidemiol Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2020.03.054_b0010","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.vaccine.2008.11.012","article-title":"Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older","volume":"27","author":"Stein","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.054_b0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2334-13-170","article-title":"Similar herpes zoster incidence across Europe: results from a systematic literature review","volume":"13","author":"Pinchinat","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2020.03.054_b0020","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a United States administrative database","volume":"20","author":"Insinga","year":"2005","journal-title":"J Gen Int Med"},{"issue":"11","key":"10.1016\/j.vaccine.2020.03.054_b0025","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.vaccine.2020.03.054_b0030","unstructured":"Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook [Internet]. Canberra: Australian Government Department of Health; 2019 [cited 21 December 2019]. Contract No.: 2 December. Available from: https:\/\/immunisationhandbook.health.gov.au."},{"issue":"22","key":"10.1016\/j.vaccine.2020.03.054_b0035","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.03.054_b0040","first-page":"CD008858","article-title":"Soares BG. Vaccines for preventing herpes zoster in older adults","volume":"3","author":"Gagliardi","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.vaccine.2020.03.054_b0045","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2020.03.054_b0050","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-152-9-201005040-00004","article-title":"Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial","volume":"152","author":"Simberkoff","year":"2010","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.vaccine.2020.03.054_b0055","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1080\/21645515.2018.1456598","article-title":"Post-licensure safety surveillance of zoster vaccine live (Zostavax) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006\u20132015","volume":"14","author":"Miller","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.03.054_b0060","unstructured":"National Centre for Immunisation Research and Surveillance. Evaluation of the National Shingles Vaccination Program Process and early impact evaluation [Internet]. Sydney: NCIRS; 2018. [cited 21 August 2019]. Available from: http:\/\/ncirs.org.au\/sites\/default\/files\/2019-04\/Shingles%20Program%20Evaluation%20Report_1%20March%202019_Final%20for%20web.pdf."},{"issue":"52","key":"10.1016\/j.vaccine.2020.03.054_b0065","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1016\/j.vaccine.2017.11.013","article-title":"Herpes zoster vaccine live: A 10year review of post-marketing safety experience","volume":"35","author":"Willis","year":"2017","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2020.03.054_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001919","article-title":"Acute cardiovascular Events after herpes zoster: a self-controlled case series analysis in vaccinated and unvaccinated older residents of the United States","volume":"12","author":"Minassian","year":"2015","journal-title":"PLoS Med"},{"issue":"11","key":"10.1016\/j.vaccine.2020.03.054_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166554","article-title":"Risk of stroke after herpes zoster - evidence from a German self-controlled case-series study","volume":"11","author":"Schink","year":"2016","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.vaccine.2020.03.054_b0080","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2796.2011.02474.x","article-title":"Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study","volume":"271","author":"Tseng","year":"2012","journal-title":"J Intern Med"},{"issue":"27","key":"10.1016\/j.vaccine.2020.03.054_b0085","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1016\/j.vaccine.2018.05.078","article-title":"Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection","volume":"36","author":"Alexander","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.054_b0090","doi-asserted-by":"crossref","DOI":"10.33321\/cdi.2019.43.29","article-title":"Surveillance of adverse events following immunisation in Australia annual report, 2017","volume":"43","author":"Dey","year":"2019","journal-title":"Commun Dis Intell"},{"key":"10.1016\/j.vaccine.2020.03.054_b0095","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-212688","article-title":"Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient","volume":"2016","author":"Costa","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2020.03.054_b0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023263","article-title":"Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia","volume":"8","author":"Pillsbury","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2020.03.054_b0105","unstructured":"National Centre for Immunisation Research and Surveillance. AusVaxSafety: An NCIRS led collaboration. [Internet] 2019 [cited 2 December 2019]. Available from: http:\/\/www.ausvaxsafety.org.au\/about-us."},{"key":"10.1016\/j.vaccine.2020.03.054_b0110","unstructured":"National Centre for Immunisation Research and Surveillance. AusVaxSafety: Zoster vaccine safety surveillance. [Internet] 2019 [cited 21 September 2019]. Available from: http:\/\/ausvaxsafety.org.au\/safety-data\/zoster-vaccine."},{"key":"10.1016\/j.vaccine.2020.03.054_b0115","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz147","article-title":"Data resource profile: MedicineInsight, an Australian national primary health care database","author":"Busingye","year":"2019","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.03.054_b0120","unstructured":"NPS MedicineWise. General Practice Insights Report July 2016\u2013June 2017: A working paper [Internet]. Sydney: NPS MedicineWise; 2018. [cited 21 September 2019]. Available from: https:\/\/www.nps.org.au\/assets\/63df68106933b7b1-100a108a779c-GPIR-2016_17_FinalVersion13-Dec.pdf."},{"key":"10.1016\/j.vaccine.2020.03.054_b0125","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2020.03.054_b0130","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1186\/s12879-015-1263-7","article-title":"Febrile seizures after 2009 influenza A (H1N1) vaccination and infection: a nationwide registry-based study","volume":"15","author":"Bakken","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"16","key":"10.1016\/j.vaccine.2020.03.054_b0135","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1016\/j.vaccine.2011.01.088","article-title":"Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia","volume":"29","author":"Buttery","year":"2011","journal-title":"Vaccine."},{"issue":"32","key":"10.1016\/j.vaccine.2020.03.054_b0140","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1016\/j.vaccine.2016.04.050","article-title":"The risk of intussusception following monovalent rotavirus vaccination in England: a self-controlled case-series evaluation","volume":"34","author":"Stowe","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.03.054_b0145","unstructured":"Australian Bureau of Statistics. Population. [Internet] 2019 [cited 18 May 2019]. Available from: https:\/\/www.abs.gov.au\/Population."},{"issue":"1","key":"10.1016\/j.vaccine.2020.03.054_b0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2307\/2533328","article-title":"Relative incidence estimation from case series for vaccine safety evaluation","volume":"51","author":"Farrington","year":"1995","journal-title":"Biometrics."},{"key":"10.1016\/j.vaccine.2020.03.054_b0155","doi-asserted-by":"crossref","first-page":"143","DOI":"10.18773\/austprescr.2012.067","article-title":"Herpes zoster: epidemiology, clinical features, treatment and prevention","volume":"35","author":"Wehrhahn","year":"2012","journal-title":"Aust Prescr."},{"issue":"11","key":"10.1016\/j.vaccine.2020.03.054_b0160","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4161\/hv.7.11.17982","article-title":"Safety and tolerability of zoster vaccine in adults >=60 years old","volume":"7","author":"Murray","year":"2011","journal-title":"Hum Vaccin"},{"issue":"47","key":"10.1016\/j.vaccine.2020.03.054_b0165","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1016\/j.vaccine.2012.08.070","article-title":"Safety of Zostavax \u2013 a cohort study in a managed care organization","volume":"30","author":"Baxter","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.054_b0170","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(09)70134-6","article-title":"Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment","volume":"8","author":"Gilden","year":"2009","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.vaccine.2020.03.054_b0175","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/aje\/kwu322","article-title":"A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program","volume":"181","author":"Baker","year":"2015","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.03.054_b0180","series-title":"A Language and Environment for Statistical Computing","author":"Core","year":"2019"},{"key":"10.1016\/j.vaccine.2020.03.054_b0185","unstructured":"Turner H, Firth D. Generalized nonlinear models in R: An overview of the gnm package; 2018."},{"issue":"1","key":"10.1016\/j.vaccine.2020.03.054_b0190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.vaccine.2017.08.029","article-title":"Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine","volume":"36","author":"Levin","year":"2018","journal-title":"Vaccine."},{"issue":"6","key":"10.1016\/j.vaccine.2020.03.054_b0195","first-page":"726","article-title":"The generalized rash: part I. Differential diagnosis","volume":"81","author":"Ely","year":"2010","journal-title":"Am Fam Phys"},{"issue":"48","key":"10.1016\/j.vaccine.2020.03.054_b0200","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1016\/j.vaccine.2018.09.018","article-title":"Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV)","volume":"36","author":"Hurley","year":"2018","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.03.054_b0205","unstructured":"Therapeutic Goods Administration. Zostavax safety advisory \u2013 not to be used in patients with compromised immune function. [Internet] 2017 [cited 12 May 2019]. Available from: https:\/\/www.tga.gov.au\/alert\/zostavax-vaccine."},{"key":"10.1016\/j.vaccine.2020.03.054_b0210","unstructured":"Public Health England (PHE). Shingles (herpes zoster): the green book, chapter 28a. [Internet] 2013 [cited 18 May 2019]. Available from: https:\/\/www.gov.uk\/government\/publications\/shingles-herpes-zoster-the-green-book-chapter-28a."},{"issue":"5","key":"10.1016\/j.vaccine.2020.03.054_b0215","doi-asserted-by":"crossref","first-page":"289","DOI":"10.31128\/AJGP-11-17-4413","article-title":"How common is multiple general practice attendance in Australia?","volume":"47","author":"Wright","year":"2018","journal-title":"Aust J Gen Pract."},{"issue":"11","key":"10.1016\/j.vaccine.2020.03.054_b0220","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.vaccine.2017.01.063","article-title":"Investigating adverse events following immunisation with pneumococcal polysaccharide vaccine using electronic General Practice data","volume":"35","author":"Trinh","year":"2017","journal-title":"Vaccine."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20304436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20304436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:42:49Z","timestamp":1759401769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20304436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":44,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0264410X20304436"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.054","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of live attenuated herpes zoster vaccine in adults 70\u201379\u00a0years: A self-controlled case series analysis using primary care data from Australia\u2019s MedicineInsight program","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}